{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:20:26Z","timestamp":1791321626919,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"22","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005690","name":"Universit\u00e4t des Saarlandes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The still increasing number of drugs of abuse, particularly the so-called new psychoactive substances (NPS), poses an analytical challenge for clinical and forensic toxicologists but also for doping control. NPS usually belong to various classes such as synthetic cannabinoids, phenethylamines, opioids, or benzodiazepines. Like other xenobiotics, NPS undergo absorption, distribution, metabolism, and excretion processes after consumption, but only very limited data concerning their toxicokinetics and safety properties is available once they appear on the market. The inclusion of metabolites in mass spectral libraries is often crucial for the detection of NPS especially in urine screening approaches. Authentic human samples may represent the gold standard for identification of metabolites but are often not available and clinical studies cannot be performed due to ethical concerns. However, numerous alternative in vitro and in vivo models are available. This trends article will give an overview on selected models, discuss current studies, and highlight recent developments.<\/jats:p>","DOI":"10.1007\/s00216-021-03311-w","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T09:07:46Z","timestamp":1617268066000},"page":"5551-5559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Recent trends in drugs of abuse metabolism studies for mass spectrometry\u2013based analytical screening procedures"],"prefix":"10.1007","volume":"413","author":[{"given":"Lea","family":"Wagmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja M.","family":"Gampfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus R.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"3311_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/164_2017_83","volume":"252","author":"L Wagmann","year":"2018","unstructured":"Wagmann L, Maurer HH. Bioanalytical methods for new psychoactive substances. Handb Exp Pharmacol. 2018;252:413\u201339.","journal-title":"Handb Exp Pharmacol"},{"issue":"7\u20138","key":"3311_CR2","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/dta.295","volume":"3","author":"FT Peters","year":"2011","unstructured":"Peters FT, Meyer MR. In vitro approaches to studying the metaboslism of new psychoactive compounds. Drug Test Anal. 2011;3(7\u20138):483\u201395.","journal-title":"Drug Test Anal."},{"key":"3311_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fchem.2019.00109","volume":"7","author":"X Diao","year":"2019","unstructured":"Diao X, Huestis MA. New synthetic cannabinoids metabolism and strategies to best identify optimal marker metabolites. Front Chem. 2019;7:109.","journal-title":"Front Chem."},{"issue":"2","key":"3311_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/03602532.2016.1188937","volume":"48","author":"KN Ellefsen","year":"2016","unstructured":"Ellefsen KN, Concheiro M, Huestis MA. Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. Drug Metab Rev. 2016;48(2):237\u201365.","journal-title":"Drug Metab Rev"},{"key":"3311_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jpba.2017.05.028","volume":"143","author":"LHJ Richter","year":"2017","unstructured":"Richter LHJ, Flockerzi V, Maurer HH, Meyer MR. Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples. J Pharm Biomed Anal. 2017;143:32\u201342.","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"3311_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/jat\/bkaa019","volume":"44","author":"L Wagmann","year":"2020","unstructured":"Wagmann L, Manier SK, Bambauer TP, Felske C, Eckstein N, Flockerzi V, et al. Toxicokinetics and analytical toxicology of flualprazolam: metabolic fate, isozyme mapping, human plasma concentration and main urinary excretion products. J Anal Toxicol. 2020;44(6):549\u201358.","journal-title":"J Anal Toxicol"},{"key":"3311_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fchem.2020.00539","volume":"8","author":"L Wagmann","year":"2020","unstructured":"Wagmann L, Frankenfeld F, Park YM, Herrmann J, Fischmann S, Westphal F, et al. How to study the metabolism of new psychoactive substances for the purpose of toxicological screenings-a follow-up study comparing pooled human liver S9, HepaRG cells, and zebrafish larvae. Front Chem. 2020;8:539.","journal-title":"Front Chem"},{"issue":"2","key":"3311_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3109\/03602532.2015.1029635","volume":"47","author":"MS Castaneto","year":"2015","unstructured":"Castaneto MS, Wohlfarth A, Desrosiers NA, Hartman RL, Gorelick DA, Huestis MA. Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab Rev. 2015;47(2):124\u201374.","journal-title":"Drug Metab Rev"},{"issue":"1","key":"3311_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/dta.2463","volume":"11","author":"M Pettersson Bergstrand","year":"2019","unstructured":"Pettersson Bergstrand M, Richter LHJ, Maurer HH, Wagmann L, Meyer MR. In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases. Drug Test Anal. 2019;11(1):45\u201350.","journal-title":"Drug Test Anal."},{"key":"3311_CR10","doi-asserted-by":"publisher","unstructured":"Wagmann L, Manier SK, Felske C, Gampfer TM, Richter MJ, Eckstein N, et al. Flubromazolam-derived designer benzodiazepines: toxicokinetics and analytical toxicology of clobromazolam and bromazolam. J Anal Toxicol. 2020. https:\/\/doi.org\/10.1093\/jat\/bkaa161.","DOI":"10.1093\/jat\/bkaa161"},{"key":"3311_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.toxlet.2020.04.001","volume":"329","author":"F Nordmeier","year":"2020","unstructured":"Nordmeier F, Doerr A, Laschke MW, Menger MD, Schmidt PH, Schaefer N, et al. Are pigs a suitable animal model for in vivo metabolism studies of new psychoactive substances? A comparison study using different in vitro\/in vivo tools and U-47700 as model drug. Toxicol Lett. 2020;329:12\u20139.","journal-title":"Toxicol Lett"},{"issue":"10","key":"3311_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1389201018666171122124401","volume":"18","author":"C Richeval","year":"2017","unstructured":"Richeval C, Gicquel T, Hugbart C, Le Dare B, Allorge D, Morel I, et al. In vitro characterization of NPS metabolites produced by human liver microsomes and the HepaRG cell line using liquid chromatography high resolution mass spectrometry (LC-HRMS) analysis: application to furanyl fentanyl. Curr Pharm Biotechnol. 2017;18(10):806\u201314.","journal-title":"Curr Pharm Biotechnol"},{"issue":"2","key":"3311_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11419-018-0425-x","volume":"36","author":"T Kanamori","year":"2018","unstructured":"Kanamori T, Togawa-Iwata Y, Segawa H, Yamamuro T, Kuwayama K, Tsujikawa K, et al. Use of hepatocytes isolated from a liver-humanized mouse for studies on the metabolism of drugs: application to the metabolism of fentanyl and acetylfentanyl. Forensic Toxicol. 2018;36(2):467\u201375.","journal-title":"Forensic Toxicol"},{"issue":"4","key":"3311_CR14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1208\/s12248-017-0078-4","volume":"19","author":"S Watanabe","year":"2017","unstructured":"Watanabe S, Kuzhiumparambil U, Nguyen MA, Cameron J, Fu S. Metabolic profile of synthetic cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans. AAPS J. 2017;19(4):1148\u201362.","journal-title":"AAPS J"},{"issue":"5","key":"3311_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/dta.2544","volume":"11","author":"KE Grafinger","year":"2019","unstructured":"Grafinger KE, Wilke A, Konig S, Weinmann W. Investigating the ability of the microbial model Cunninghamella elegans for the metabolism of synthetic tryptamines. Drug Test Anal. 2019;11(5):721\u20139.","journal-title":"Drug Test Anal."},{"issue":"18","key":"3311_CR16","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/rcm.6673","volume":"27","author":"N De Brabanter","year":"2013","unstructured":"De Brabanter N, Esposito S, Tudela E, Lootens L, Meuleman P, Leroux-Roels G, et al. In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom. 2013;27(18):2115\u201326.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"1","key":"3311_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/dta.2899","volume":"13","author":"N Walle","year":"2021","unstructured":"Walle N, Nordmeier F, Doerr AA, Peters B, Laschke MW, Menger MD, et al. Comparison of in vitro and in vivo models for the elucidation of metabolic patterns of 7-azaindole-derived synthetic cannabinoids exemplified using cumyl-5F-P7AICA. Drug Test Anal. 2021;13(1):74\u201390.","journal-title":"Drug Test Anal"},{"issue":"11\u201312","key":"3311_CR18","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/dta.2523","volume":"10","author":"VF Sardela","year":"2018","unstructured":"Sardela VF, Anselmo CS, Nunes I, Carneiro GRA, Dos Santos GRC, de Carvalho AR, et al. Zebrafish (Danio rerio) water tank model for the investigation of drug metabolism: progress, outlook, and challenges. Drug Test Anal. 2018;10(11\u201312):1657\u201369.","journal-title":"Drug Test Anal."},{"issue":"1","key":"3311_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11419-019-00498-7","volume":"38","author":"LHJ Richter","year":"2019","unstructured":"Richter LHJ, Menges J, Wagmann L, Brandt SD, Stratford A, Westphal F, et al. In vitro toxicokinetics and analytical toxicology of three novel NBOMe derivatives: phase I and II metabolism, plasma protein binding, and detectability in standard urine screening approaches studied by means of hyphenated mass spectrometry. Forensic Toxicol. 2019;38(1):141\u201359.","journal-title":"Forensic Toxicol"},{"issue":"23","key":"3311_CR20","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1007\/s00216-016-9740-4","volume":"408","author":"LH Richter","year":"2016","unstructured":"Richter LH, Kaminski YR, Noor F, Meyer MR, Maurer HH. Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. Anal Bioanal Chem. 2016;408(23):6283\u201394.","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"3311_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11419-020-00562-7","volume":"39","author":"HS Leong","year":"2020","unstructured":"Leong HS, Watanabe S, Kuzhiumparambil U, Fong CY, Moy HY, Yao YJ, et al. Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. Forensic Toxicol. 2020;39(1):198\u2013212.","journal-title":"Forensic Toxicol"},{"issue":"1","key":"3311_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.dmpk.2017.11.001","volume":"33","author":"Y Naritomi","year":"2018","unstructured":"Naritomi Y, Sanoh S, Ohta S. Chimeric mice with humanized liver: application in drug metabolism and pharmacokinetics studies for drug discovery. Drug Metab Pharmacokinet. 2018;33(1):31\u20139.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"3311_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1248\/bpb.b18-00765","volume":"42","author":"T Kanamori","year":"2019","unstructured":"Kanamori T, Iwata YT, Segawa H, Yamamuro T, Kuwayama K, Tsujikawa K, et al. Metabolism of butyrylfentanyl in fresh human hepatocytes: chemical synthesis of authentic metabolite standards for definitive identification. Biol Pharm Bull. 2019;42(4):623\u201330.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"3311_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11419-013-0179-4","volume":"31","author":"N De Brabanter","year":"2013","unstructured":"De Brabanter N, Esposito S, Geldof L, Lootens L, Meuleman P, Leroux-Roels G, et al. In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122). Forensic Toxicol. 2013;31(2):212\u201322.","journal-title":"Forensic Toxicol"},{"key":"3311_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.toxlet.2016.04.021","volume":"253","author":"N Schaefer","year":"2016","unstructured":"Schaefer N, Wojtyniak JG, Kettner M, Schlote J, Laschke MW, Ewald AH, et al. Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. Toxicol Lett. 2016;253:7\u201316.","journal-title":"Toxicol Lett"},{"key":"3311_CR26","doi-asserted-by":"publisher","unstructured":"Doerr AA, Nordmeier F, Walle N, Laschke MW, Menger MD, Schmidt PH, et al. Can a recently developed pig model be used for in vivo metabolism studies of 7-azaindole derived synthetic cannabinoids? A study using 5F-MDMB-P7AICA. J Anal Toxicol. 2020. https:\/\/doi.org\/10.1093\/jat\/bkaa122.","DOI":"10.1093\/jat\/bkaa122"},{"key":"3311_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.toxlet.2019.01.010","volume":"305","author":"LHJ Richter","year":"2019","unstructured":"Richter LHJ, Herrmann J, Andreas A, Park YM, Wagmann L, Flockerzi V, et al. Tools for studying the metabolism of new psychoactive substances for toxicological screening purposes - a comparative study using pooled human liver S9, HepaRG cells, and zebrafish larvae. Toxicol Lett. 2019;305:73\u201380.","journal-title":"Toxicol Lett"},{"key":"3311_CR28","doi-asserted-by":"crossref","unstructured":"Park YM, Meyer MR, Muller R, Herrmann J. Drug administration routes impact the metabolism of a synthetic cannabinoid in the zebrafish larvae model. Molecules. 2020;25(19).","DOI":"10.3390\/molecules25194474"},{"issue":"2","key":"3311_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/dta.2493","volume":"11","author":"LHJ Richter","year":"2019","unstructured":"Richter LHJ, Maurer HH, Meyer MR. Metabolic fate of the new synthetic cannabinoid 7\u2032N-5F-ADB in rat, human, and pooled human S9 studied by means of hyphenated high-resolution mass spectrometry. Drug Test Anal. 2019;11(2):305\u201317.","journal-title":"Drug Test Anal."},{"key":"3311_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.actbio.2020.08.041","volume":"116","author":"E Moradi","year":"2020","unstructured":"Moradi E, Jalili-Firoozinezhad S, Solati-Hashjin M. Microfluidic organ-on-a-chip models of human liver tissue. Acta Biomater. 2020;116:67\u201383.","journal-title":"Acta Biomater"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-021-03311-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00216-021-03311-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-021-03311-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:03:45Z","timestamp":1630541025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00216-021-03311-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":30,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3311"],"URL":"https:\/\/doi.org\/10.1007\/s00216-021-03311-w","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The content of this article required no approval from an ethics committee. The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}